title: Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers.
abstract: Approximately 90% of T2D patients in the US are diagnosed and treated in the primary care setting, and the majority of the burden of disease management falls to primary care providers. Here, we discuss the clinical data for once weekly dulaglutide, e.g. the results of seven completed Phase 3 trials, patient preference studies, patient reported outcomes (PRO), and clinical data surrounding the dulaglutide administration device. Dulaglutide 1.5 mg once weekly demonstrated superiority to placebo, metformin, sitagliptin, exenatide BID, and insulin glargine (in 2 trials), and non-inferiority to liraglutide in reduction of HbA1c from baseline, with an acceptable safety profile. Dulaglutide-treated patients achieved the composite endpoint of an HbA1c <7.0% with no hypoglycemia, no severe hypoglycemia, and no weight gain significantly more than metformin, sitagliptin, exenatide BID or insulin glargine treated patients. Dulaglutide consistently showed an early onset of glycemic control, lasting up to 104 weeks. Additionally, PRO and patient preference data support the benefit of once weekly dulaglutide for the treatment of T2D.
authors.affiliation: a The Frist Clinic , Nashville , TN , USA.
authors.forename: John E
authors.initials: JE
authors.lastname: Anderson
authors.affiliation: b Global Medical Affairs , Eli Lilly and Company, Lilly Corporate Center , Indianapolis , IN , USA.
authors.forename: Vivian T
authors.initials: VT
authors.lastname: Thieu
authors.affiliation: c Global Patient Outcomes , Eli Lilly and Company, Lilly Corporate Center , Indianapolis , IN , USA.
authors.forename: Kristina S
authors.initials: KS
authors.lastname: Boye
authors.affiliation: d Global Scientific Communications , Eli Lilly and Company, Lilly Corporate Center , Indianapolis , IN , USA.
authors.forename: Ryan T
authors.initials: RT
authors.lastname: Hietpas
authors.affiliation: b Global Medical Affairs , Eli Lilly and Company, Lilly Corporate Center , Indianapolis , IN , USA.
authors.forename: Luis-Emilio
authors.initials: LE
authors.lastname: Garcia-Perez
mesh_terms: D001786:Blood Glucose; D001835:Body Weight / Q000187:drug effects; D017326:Clinical Trials, Phase III as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D004763:Glucagon-Like Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006442:Glycated Hemoglobin; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007141:Immunoglobulin Fc Fragments / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007279:Injections, Subcutaneous / Q000295:instrumentation; D000071066:Patient Reported Outcome Measures; D011320:Primary Health Care; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D004763:Glucagon-Like Peptides; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007141:Immunoglobulin Fc Fragments; D011993:Recombinant Fusion Proteins; C555680:dulaglutide
keywords: Dulaglutide; GLP-1 receptor agonist; diabetes; efficacy; incretin; patient preference; patient reported outcomes; safety